UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 19, 2015
ROCK CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
(State or other jurisdiction of incorporation) |
000-15324
(Commission File Number) |
52-1402131
(IRS Employer Identification No.) |
| |
|
|
| |
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
844-727-0727
(Registrant’s telephone number,
including area code) |
|
| |
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On August 19, 2015, Rock Creek Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing participation and presentation at a pharmaceutical industry
conference in Boston to be held on September 15-17, 2015. The Company regularly participates in such conferences in the ordinary
course of its business. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Current Report on
Form 8-K shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. |
Description |
| |
|
| 99.1 |
Press Release, dated August 19, 2015 |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
ROCK CREEK PHARMACEUTICALS, INC. |
| |
|
| |
By: |
/s/ Michael J. Mullan |
| |
|
Michael J. Mullan
Chairman of the Board and Chief Executive Officer |
Date: August 19, 2015
Exhibit 99.1
Rock Creek Pharmaceuticals to Present at
the Annual BioPharm America
International Partnering Conference
Sarasota, Fl., August 19, 2015 /PRNewswire/
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a clinical stage, drug development company
which has focused on the application of its lead compounds to chronic inflammatory conditions, announced that the Company has been
invited to present at BioPharm America 2015 in Boston (Sept. 15-17, 2015) at The Boston
Marriott Copley Place.
Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals,
will present clinical data associated with the Company’s ongoing drug development initiatives. as well as an update to the
company’s corporate and regulatory strategy.
About BioPharm America 2015
BioPharm
America™ is where biotech industry partnerships get started.
Meet face-to-face with biotech and pharma executives from around the world to identify and enter into strategic relationships.
Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD
Group’s acclaimed European events BIO-Europe® and
BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2015 on Twitter: @EBDGroup
(hashtag: #BPA15).
About Anatabine Citrate:
Rock Creek Pharmaceuticals’ compound
is a small molecule, cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics, distinct from other
anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company has sponsored
extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering
models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. All these studies demonstrated the anti-inflammatory
effects of the Company’s compound. In addition, the Company's compilation of human exposure, safety and tolerability data,
derived primarily from human clinical studies and post-marketing data collection of the previously marketed nutraceutical product,
has provided important insights for clinical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is clinical
stage drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds
that provide therapies for chronic and acute inflammatory diseases.
For more information, visit: http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this
release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "targets," "projects" and similar expressions.
The statements in this release are based upon the current beliefs and expectations of our company's management and are subject
to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous
factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources
to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new
product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect
of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability
to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation,
potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well
as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015. We undertake no duty to update
any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy & Development
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharmaceuticals.com